Scarica l'app Stockscreener
0.478
8.09%
-0.0421
Dopo l'orario di chiusura:
.48
0.002
+0.42%
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Finansavisen
A new billing code was approved for a tool that collects esophageal cells. Medicare payment remains pending. - Stock Titan
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - Yahoo Finance
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9.5 - Moomoo
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 - Eastern Progress
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Benzinga
LUCD Q1 2026 Earnings: EPS Misses by 100.7% as Commercialization Costs MountROIC Trend Report - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - Yahoo Finance
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com India
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93Imbalance Zone - vinanet.vn
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 revenue jumps to $33k; $30m warrants issued - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Finansavisen
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportUnusual Put Volume - vinanet.vn
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Lucid Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Nigeria
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Australia
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com India
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com Canada
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com UK
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
1.48%
3.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):